This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Psychogenic polydipsia

Authoring team

Psychogenic polydipsia is an uncommon clinical disorder characterized by excessive water-drinking in the absence of a physiologic stimulus to drink. The excessive water-drinking is well tolerated unless hyponatraemia supervenes (1). The level of hyponatraemia used in one study was below 130 mmol/L (2). Classically this disorder has been described in hospitalised schizophrenics. Also it may occur in children, as a symptom of emotional difficulties or as an isolated phenomenon in a child who simply enjoys drinking.

The diagnosis of psychogenic polydipsia is one of exclusion and requires specialist investigation and management; the most important test is the water deprivation test which should be undertaken carefully. Note that chronic psychogenic polydipsia may actually impair the response of the kidneys to ADH, and therefore reduce the renal concentrating ability. Equivocal results should be interpreted with caution.

Clozapine is an atypical antipsychotic drug that has been demonstrated to be a highly effective treatment for polydipsia in schizophrenic patients. There has also been the successful use of clozapine in psychogenic polydipsia in a non-schizophrenic patient (3).

Reference:

  1. Psychogenic polydipsia with hyponatremia: report of eleven cases. Am J Kidney Dis. 1987 May;9(5):410-6.
  2. Arch Intern Med. 1995 May 8;155(9):953-7.
  3. Hum Psychopharmacol. 2002 Jul;17(5):253-5.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.